JPMorgan Chase & Co. Raises Cellebrite DI (NASDAQ:CLBT) Price Target to $28.00

Cellebrite DI (NASDAQ:CLBT) had its target price raised by research analysts at JPMorgan Chase & Co. from $24.00 to $28.00 in a research note issued to investors on Tuesday,Benzinga reports. The firm currently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s target price points to a potential upside of 9.98% from the stock’s current price.

A number of other research analysts have also recently commented on the company. Craig Hallum boosted their price objective on Cellebrite DI from $23.00 to $24.00 and gave the stock a “buy” rating in a research note on Thursday, November 7th. Needham & Company LLC upped their price target on Cellebrite DI from $21.00 to $28.00 and gave the stock a “buy” rating in a report on Wednesday, January 22nd. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $22.14.

Cellebrite DI Stock Up 0.2 %

Cellebrite DI stock opened at $25.46 on Tuesday. The firm has a fifty day moving average of $22.31 and a 200-day moving average of $18.89. Cellebrite DI has a 52-week low of $8.91 and a 52-week high of $26.30. The firm has a market capitalization of $5.24 billion, a P/E ratio of -16.43, a PEG ratio of 3.72 and a beta of 1.47.

Institutional Investors Weigh In On Cellebrite DI

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Pathway Financial Advisers LLC raised its position in shares of Cellebrite DI by 1,583.8% during the 3rd quarter. Pathway Financial Advisers LLC now owns 4,378 shares of the company’s stock worth $74,000 after purchasing an additional 4,118 shares during the period. Tower View Wealth Management LLC increased its position in Cellebrite DI by 1.2% in the third quarter. Tower View Wealth Management LLC now owns 130,647 shares of the company’s stock worth $2,200,000 after buying an additional 1,500 shares during the period. Meitav Investment House Ltd. boosted its holdings in shares of Cellebrite DI by 29.7% during the third quarter. Meitav Investment House Ltd. now owns 2,066,322 shares of the company’s stock valued at $34,797,000 after acquiring an additional 473,293 shares during the period. Pembroke Management LTD increased its holdings in shares of Cellebrite DI by 24.3% in the 3rd quarter. Pembroke Management LTD now owns 1,908,345 shares of the company’s stock worth $32,137,000 after acquiring an additional 372,619 shares during the period. Finally, Janney Montgomery Scott LLC lifted its position in Cellebrite DI by 8.3% in the 3rd quarter. Janney Montgomery Scott LLC now owns 51,155 shares of the company’s stock valued at $861,000 after purchasing an additional 3,912 shares during the last quarter. 45.88% of the stock is currently owned by hedge funds and other institutional investors.

Cellebrite DI Company Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.